| 3,3'-Diindolylmethane | |
|---|---|
![]() |
|
| IUPAC name |
3,3′-methanediylbis(1H-indole)
|
| Other names | 3-(1H-Indol-3-ylmethyl)-1H-indole 3,3'-Methylenebis-1H-indole DIM |
| Identifiers | |
| CAS number | 1968-05-4 |
| PubChem | 3071 |
| SMILES |
C1=CC=C2C(=C1)C(=CN2)CC3=CNC4=CC=CC=C43
|
| InChI |
1/C17H14N2/c1-3-7-16-14(5-1)12(10-18-16)9-13-11-19-17-8-4-2-6-15(13)17/h1-8,10-11,18-19H,9H2
|
| Properties | |
| Molecular formula | C17H14N2 |
| Molar mass | 246.31 g mol−1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
3,3′-Diindolylmethane or DIM is an anticarcinogen compound derived from the digestion of indole-3-carbinol, found in Brassica vegetables such as broccoli and cauliflower. The reputation of Brassica vegetables as medicinal plants rests in part on the activities of diindolylmethane.
Contents |
DIM has the biological properties listed in the chart below. Because of its various potent anti-cancer properties, the National Cancer Institute of the United States has begun clinical trials of DIM as a therapeutic for numerous forms of cancer. Due to its innate immune modulating properties (potentiation of Interferon-Gamma receptors and production), DIM is also under investigation as a treatment for a variety of viral infections and antibiotic resistant bacteria. As DIM has been demonstrated to synergize with Interferon-Gamma in the potentiation of the MHC-I Complex, it is currently also under investigation as an adjuvant to IFN-G treatment models for both cancer and viral infections such as HIV, HPV and Hepatitis.
DIM is currently used to treat Recurring Respiratory Papillomatosis, a rare respiratory disease with tumors in the upper respiratory tracts caused by the Human Papilloma Virus. DIM is additionally in Phase III clinical trials for Cervical dysplasia, a pre-cancerous condition also caused by the Human Papilloma Virus.
A search of internet websites on November 7, 2009 of both the National Cancer Institute (United States) and registered cancer trials (United States, at http://clinicaltrials.gov/ct2/results?intr=%22Indole%22) shows five cancer treatment trials of 3,3'-diindolylmethane (DIM). Four of these trials have been completed or are not currently recruiting. No study results are posted for these four trials. The fifth trial is ongoing and recruiting subjects. It is stated "To measure the level of diindolylmethane in prostate tissue after treatment with oral microencapsulated diindolylmethane (B-DIM) in patients with stage I or II adenocarcinoma of the prostate undergoing radical prostatectomy." The trial sponsors include the Barbara Ann Karmanos Cancer Institute (Detroit, MI) and the National Cancer Institute. It is currently enrolling patients at three sites. It is said that DIM is also being investigated as a potential treatment for a variety of viral and anti-biotic resistant bacterial infections, as well.
| 3,3'-Diindolylmethane | |
|---|---|
| File:3,3' | |
| 3,3′-methanediylbis(1H-indole) | |
| Other names 3-(1H-Indol-3-ylmethyl)-1H-indole 3,3'-Methylenebis-1H-indole DIM | |
| Identifiers | |
| CAS number | 1968-05-4 |
| PubChem | 3071 |
| SMILES | C1=CC=C2C(=C1)C(=CN2)CC3=CNC4=CC=CC=C43
|
| InChI | InChI=1/C17H14N2/c1-3-7-16-14(5-1)12(10-18-16)9-13-11-19-17-8-4-2-6-15(13)17/h1-8,10-11,18-19H,9H2
|
| Properties | |
| Molecular formula | C17H14N2 |
| Molar mass | 246.31 g mol−1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
3,3′-Diindolylmethane or DIM is an anticarcinogen compound derived from the digestion of indole-3-carbinol, found in Brassica vegetables such as broccoli, cauliflower, and collard greens.[citation needed] The reputation of Brassica vegetables as medicinal plants rests in part on the activities of diindolylmethane.[citation needed]
Contents |
DIM has the biological properties listed in the chart below. Because of its various potent anti-cancer properties, the National Cancer Institute of the United States has begun clinical trials of DIM as a therapeutic for numerous forms of cancer.[citation needed] Due to its innate immune-modulating properties (potentiation of Interferon-Gamma receptors and production),[citation needed] DIM is also under investigation as a treatment for a variety of viral infections and antibiotic-resistant bacteria.[citation needed] As DIM has been demonstrated to synergize with Interferon-Gamma in the potentiation of the MHC-I Complex,[citation needed] it is currently also under investigation as an adjuvant to IFN-G treatment models for both cancer and viral infections such as HIV, HPV and Hepatitis.
At the present time, DIM is used to treat Recurring Respiratory Papillomatosis, a rare respiratory disease with tumors in the upper respiratory tracts caused by the Human Papilloma Virus.[citation needed] In addition, DIM is in Phase III clinical trials for Cervical dysplasia, a pre-cancerous condition also caused by the Human Papilloma Virus.[citation needed]
A search of internet websites on November 7, 2009 of both the National Cancer Institute (United States) and registered cancer trials (United States, at http://clinicaltrials.gov/ct2/results?intr=%22Indole%22) shows five cancer treatment trials of 3,3'-diindolylmethane (DIM). Four of these trials have been completed or are not currently recruiting. No study results are posted for these four trials. The fifth trial is ongoing and recruiting subjects. It is stated "To measure the level of diindolylmethane in prostate tissue after treatment with diindolylmethane (DIM) in patients with stage I or II adenocarcinoma of the prostate undergoing radical prostatectomy." The trial sponsors include the Barbara Ann Karmanos Cancer Institute (Detroit, MI) and the National Cancer Institute. It is currently enrolling patients at three sites. It is said that DIM is also being investigated as a potential treatment for a variety of viral and antibiotic-resistant bacterial infections, as well.
|
|